Trade

with

Threshold Pharmaceuticals Inc
(NASDAQ: THLD)
AdChoices
3.01
+0.03
+1.01%
After Hours :
3.01
0.00
0.00%

Open

2.98

Previous Close

2.98

Volume (Avg)

450.72k (729.43k)

Day's Range

2.94-3.01

52Wk Range

2.82-5.93

Market Cap.

178.69M

Dividend Rate ( Yield )

-

Beta

2.39

Shares Outstanding

59.37M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 12.50M

    • Net Income

    • -28.42M

    • Market Cap.

    • 178.69M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -103.88

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.39

    • Forward P/E

    • -4.60

    • Price/Sales

    • 13.39

    • Price/Book Value

    • -6.33

    • Price/Cash flow

    • -7.81

      • EBITDA

      • -24.52M

      • Return on Capital %

      • -15.15

      • Return on Equity %

      • -

      • Return on Assets %

      • -15.15

      • Book Value/Share

      • -0.48

      • Shares Outstanding

      • 59.37M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 13.67

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.70

        • Cashflow Estimate

        • -0.60

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 15.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 54.05

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -103.17

            • 39.38

            • Net Profit Margin

            • -103.88

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.57

              • 2.92

              • Quick Ratio

              • 2.47

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.48

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.41

                • 217.39

                • P/E Ratio 5-Year High

                • -38.39

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.05

                • 124.82

                • Price/Sales Ratio

                • 13.33

                • 9.52

                • Price/Book Value

                • -6.31

                • 8.61

                • Price/Cash Flow Ratio

                • -7.81

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -15.15

                    (-82.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.15

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -26.02M
                  Operating Margin
                  -208.28
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.81
                  Ownership

                  Institutional Ownership

                  57.00%

                  Top 10 Institutions

                  36.85%

                  Mutual Fund Ownership

                  28.67%

                  Float

                  88.02%

                  5% / Insider Ownership

                  9.29%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • UBS (Lux) EF Biotech (USD)

                  •  

                    1,861,294

                  • 0.00

                  • 3.14

                  • Federated Kaufmann Fund

                  •  

                    1,767,000

                  • 0.00

                  • 2.98

                  • Franklin Biotechnology Discovery

                  •  

                    1,352,800

                  • 27.00

                  • 2.28

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,262,685

                  • 0.00

                  • 2.13

                  • JPMorgan Small Cap Growth

                  •  

                    887,543

                  • 0.59

                  • 1.50

                  • Vanguard Total Stock Mkt Idx

                  •  

                    847,950

                  • 0.00

                  • 1.43

                  • iShares Russell 2000 (AU)

                  •  

                    792,539

                  • -1.46

                  • 1.10

                  • Franklin Biotechnology Discovery Fund

                  •  

                    616,100

                  • 0.00

                  • 1.04

                  • AXA Framlington Biotech

                  •  

                    589,286

                  • 0.00

                  • 0.97

                  • Vanguard Extended Market Index Fund

                  •  

                    458,370

                  • 0.19

                  • 0.77

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sutter Hill Ventures

                  •  

                    4,538,993

                  • +13.54%

                  • 7.66

                  • J.P. Morgan Investment Management Inc.

                  •  

                    2,651,390

                  • -1.41%

                  • 4.47

                  • Federated Global Inv Mgmt Corp

                  •  

                    2,391,400

                  • +273.56%

                  • 4.03

                  • BlackRock Fund Advisors

                  •  

                    2,349,795

                  • +2.41%

                  • 3.96

                  • Franklin Advisers, Inc.

                  •  

                    1,968,900

                  • +4.51%

                  • 3.32

                  • UBS Global Asset Management Zurich

                  •  

                    1,861,294

                  • 0.00%

                  • 3.14

                  • Baker Bros Advisors LLC

                  •  

                    1,826,358

                  • 0.00%

                  • 3.08

                  • Fidelity Management and Research Company

                  •  

                    1,725,169

                  • 0.00%

                  • 2.91

                  • Vanguard Group, Inc.

                  •  

                    1,404,880

                  • -3.61%

                  • 2.37

                  • State Street Corp

                  •  

                    1,134,971

                  • -5.24%

                  • 1.91

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Threshold Pharmaceuticals, Inc. is a Delaware corporation incorporated on October 17, 2001. It’s a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatm...moreents for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug (“HAP”) product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for developme...morent and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient (“API”), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.lessless

                  Key People

                  Harold E. Selick,PhD

                  CEO/Director

                  Mr. Joel Fernandes

                  Chief Accounting Officer/Controller/Vice President, Divisional

                  Nipun Davar

                  Vice President, Divisional

                  Dr. Jeffrey W. Bird, M.D.

                  Director

                  Bruce C. Cozadd

                  Director

                  • Threshold Pharmaceuticals Inc

                  • 170 Harbor Way

                  • South San Francisco, CA 94063

                  • USA.Map

                  • Phone: +1 650 474-8200

                  • Fax: +1 650 474-2529

                  • thresholdpharm.com

                  Incorporated

                  2001

                  Employees

                  58

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: